Format

Send to

Choose Destination
Congenit Heart Dis. 2019 Jan;14(1):46-51. doi: 10.1111/chd.12708.

PDA: To treat or not to treat.

Author information

1
Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Palo Alto, California.

Abstract

Management of patent ductus arteriosus in extremely preterm infants remains a topic of debate. Treatment to produce ductal closure was widely practiced until the past decade, despite lack of evidence that it decreases morbidities or mortality. Meta-analyses of trials using nonsteroidal anti-inflammatory drugs have shown effectiveness in accelerating ductal closure, but no reduction in neonatal morbidities, regardless of agent used, indication, timing, gestational age, or route of administration. Surgical ligation closes the ductus but is associated with adverse effects. Recent experience with conservative approaches to treatment suggest improved neonatal outcomes and a high rate of spontaneous ductal closure after discharge. Careful postdischarge follow-up is important, however, because potential adverse effects of long-standing aortopulmonary shunts may be an indication for catheter-based ductal closure. Identification of extremely preterm infants at greatest risk of potential harm from a persistently patent ductus, who may benefit most from treatment are urgently needed.

KEYWORDS:

bronchopulmonary dysplasia; indomethacin; patent ductus arteriosus; preterm

PMID:
30811796
DOI:
10.1111/chd.12708
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center